Ausgabe 4/1999
Inhalt (8 Artikel)
Enhanced antitumor activity of a combination treatment with a mouse/human chimeric anti-MK-1 antibody and lymphokine-activated killer cells in vitro and in a severe combined immunodeficient mouse xenograft model
Takafumi Yamamoto, Fumiko Arakawa, Ken Nakamura, Tarumi Senba, Yoshihiro Tomita, Seiyo Ikeda, Masahide Kuroki
Efficacy of repeated cycles of chemo-immunotherapy with Thymosin α1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery
Gianfranco Silecchia, Enrico Guarino, Paola Sinibaldi-Vallebona, Pasquale Pierimarchi, Angelo Restuccia, Erasmo Spaziani, Paola Bernard, Cynthia Tuthill, Enrico Garaci, Guido Rasi
Induction of preferential cytotoxicity against allogeneic mouse lymphoma cells: in vitro and in vivo studies
Benny Leshem, Yael Dorfman, Eli Kedar
Generation of specific antitumor reactivity by the stimulation of spleen cells from gastric cancer patients with MAGE-3 synthetic peptide
Tatsuo Fujie, Fumiaki Tanaka, Kouichirou Tahara, Jian Li, Shinji Tanaka, Masaki Mori, Hiroaki Ueo, Kazutoh Takesako, Tsuyoshi Akiyoshi
Immunogenicity of tumor peptides: importance of peptide length and stability of peptide/MHC class II complex
Ursula Grohmann, Maria Laura Belladonna, Roberta Bianchi, Ciriana Orabona, Silvia Silla, Giuseppe Squillacioti, Maria Cristina Fioretti, Paolo Puccetti
Semiquantitative analysis of Th1 and Th2 cytokine expression in CD3+, CD4+, and CD8+renal-cell-carcinoma-infiltrating lymphocytes
Ursula Elsässer-Beile, Thomas Grussenmeyer, Dorothee Gierschner, Barbara Schmoll, Wolfgang Schultze-Seemann, Ulrich Wetterauer, Jürgen Schulte Mönting
Investigating the lysis of small-cell lung cancer cell lines by activated natural killer (NK) cells with a fluorometric assay for NK-cell-mediated cytotoxicity
C. Lehmann, B. Glass, M. Zeis, N. Schmitz, L. Uharek
Prerequisites for the Immunotherapy of Cancer
Graham Pawelec, Andrea Engel, Medi Adibzadeh